EUVIMEDEUVIMED entdecken
Crossref

Ritlecitinib (Litfulo) for Severe Alopecia Areata

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1690a ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Alopecia Areata, Janus Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved ritlecitinib (Litfulo – Pfizer), an oral JAK and TEC kinase family inhibitor, for treatment of severe alopecia areata in patients ≥12 years old. Ritlecitinib is the second oral drug to be approved in the US for treatment of severe alopecia areata; baricitinib (Olumiant), a JAK inhibitor, is approved only for use in adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataJanus Kinase InhibitorsHumansProtein Kinase InhibitorsImmunologic Factors

Stichwörter der Autor:innen

JakafiLitfuloOlumiantXeljanzadverse effectsalopeciabaricitinibdosagedrug interactionsefficacylactationpregnancyritlecitinibruxolitinibsafety

Substanzen

Protein Kinase InhibitorsJanus Kinase InhibitorsImmunologic Factors

Zitieren

APA

(2023). Ritlecitinib (Litfulo) for Severe Alopecia Areata. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1690a

Vancouver

Ritlecitinib (Litfulo) for Severe Alopecia Areata. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1690a

BibTeX
@article{euvimed2023,
  title = {Ritlecitinib (Litfulo) for Severe Alopecia Areata},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1690a}
}
Kostenlos starten →